Louis Bont, MD, PhD, is Paediatric Infectious Diseases Specialist and Leader of the RSV Research Group at the University Medical Center Utrecht in Utrecht, The Netherlands.
THERAPEUTIC ARES AND EXPERTISE
Louis Bont earned his medical degree from the University of Amsterdam, The Netherlands. He completed a residency in pediatrics at the Wilhelmina Children’s Hospital, University Medical Center in Utrecht, The Netherlands and served there as a fellow of pediatric infectious diseases. Prof. Bont has also worked as a post-doctoral research fellow at the University Texas Medical Center, Galveston, TX.
The RSV Research Group led by Prof. Bont has the ambition to decrease the global burden of respiratory syncytial virus (RSV) bronchiolitis. The group has performed basic studies on RSV bronchiolitis, as well as 2 large birth cohort studies. In addition, Prof. Bont is the principal investigator of 2 multi-center randomized trials. He has served as an advisor of the Maternal and Neonatal Health Group of the European Parliament. Prof. Bont has authored many articles and book chapters on RSV bronchiolitis. He has served as reviewer for Lancet, British Medical Journal, Journal of Allergy and Clinical Immunology, Journal of Infectious Diseases, European Respiratory Journal, European, Thorax, American Journal of Respiratory and Critical Care Medicine and Pediatrics.
Louis Bont is involved in a number of networks. He often chaired the Global Expert Meeting, a conference on Respiratory Viruses in Europe as well as in South America. He is the founder of the Training of Upcoming Leaders In Pediatric Science (TULIPS) program, a career training program for young talented researchers. Furthermore, he is actively involved in the EUREKA network, an international high-quality translational medicine network. He also leads the Dutch RSV Neonatal Network, consisting of over fifty Dutch hospitals. Prof. Bont is a member of the ESPID Research Committee and leads the respiratory research agenda of this committee.
In January 2014, Louis Bont and Julius Clinical launched the RESViNET network, to combine expertise and leadership in order to decrease the global burden of RSV infection in infants and young children. He holds the position of Chairman in the RESViNET Board. Please visit www.resvinet.org for more information.